Document Detail


Treatment of hyperlipidaemia with fenofibrate and related fibrates.
MedLine Citation:
PMID:  18808320     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Fenofibrate is the most widely used fibrate. Its efficacy and tolerability in the treatment of hypertriglyceridaemia and combined hyperlipidaemia have been demonstrated in several clinical trials. OBJECTIVE: To review the pharmacology, lipid-lowering and extra-lipid effects of fenofibrate and to preview ABT-335, an investigational new fenofibric acid molecule. RESULTS: The effects of fenofibrate are mediated through the active metabolite fenofibric acid, and are described in detail in the paper. ABT-335 is a salt of fenofibric acid and, unlike fenofibrate, does not require first pass metabolism to the active moiety. ABT-335 is being developed for combination use with statins, and has recently completed three large Phase III randomised controlled trials in which the efficacy and safety of ABT-335 in combination with the three most commonly prescribed statins, atorvastatin, simvastatin and rosuvastatin, was evaluated in patients with mixed dyslipidaemia. CONCLUSION: ABT-335 in combination with statins may provide a safe and efficacious treatment modality that enables achievement of several therapeutic goals in patients with mixed dyslipidaemia who have high cardiovascular risk.
Authors:
Theodosios Filippatos; Haralampos J Milionis
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  17     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-23     Completed Date:  2008-12-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1599-614     Citation Subset:  IM    
Affiliation:
University of Ioannina, School of Medicine, Department of Internal Medicine, 451 10 Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiography
Antilipemic Agents / therapeutic use*
Clinical Trials as Topic
Drug Interactions
Drug Therapy, Combination
Fluorobenzenes / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hyperlipidemias / drug therapy*
Lipids / blood
Procetofen / adverse effects,  analogs & derivatives*,  pharmacokinetics,  pharmacology,  therapeutic use*
Pyrimidines / therapeutic use
Sulfonamides / therapeutic use
Chemical
Reg. No./Substance:
0/2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid; 0/Antilipemic Agents; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin; 49562-28-9/Procetofen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Next Document:  Hug Tightly and Say Goodbye: Role of Endothelial ICAM-1 in Leukocyte Transmigration.